Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)

NCT01635764 is registered in ClinicalTrials.gov with AbbVie (prior sponsor, Abbott) as lead sponsor.

NCT NCT01635764
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01635764 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Open-Label Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Hidradenitis Suppurativa - PIONEER (Open-Label Extension)
Lead sponsor
AbbVie (prior sponsor, Abbott)
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2012
Completion date
August 31, 2016
Enrollment
508 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hidradenitis suppurativa